Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Slides:

Advertisements

Similar presentations

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

Advertisements

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

My Approach to the Patient With Familial Hypercholesterolemia

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol,

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Eveline Oestreicher Stock, MD, Christine T

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Volume 67, Issue 4, Pages (April 2005)

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep C. Defesche, PhD, Gisle Langslet, MD, Paul N. Hopkins, MD, MSPH, John J.P. Kastelein, MD, PhD, FESC, Marie T. Baccara-Dinet, MD, MSc, Werner Seiz, MD, Sara Hamon, MA, PhD, Poulabi Banerjee, PhD, Claudia Stefanutti, MD, PhD Journal of Clinical Lipidology Volume 12, Issue 2, Pages 390-396.e8 (March 2018) DOI: 10.1016/j.jacl.2017.12.008 Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 Percentage change from baseline in LDL-C at (A) week 12 and (B) week 24 for individual patients. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; N/A, not available. Journal of Clinical Lipidology 2018 12, 390-396.e8DOI: (10.1016/j.jacl.2017.12.008) Copyright © 2018 National Lipid Association Terms and Conditions

Supplementary Figure 1 Percentage change from baseline in ApoB at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; NA, not available. Journal of Clinical Lipidology 2018 12, 390-396.e8DOI: (10.1016/j.jacl.2017.12.008) Copyright © 2018 National Lipid Association Terms and Conditions

Supplementary Figure 2 Percentage change from baseline in Lp(a) at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; Lp(a), lipoprotein (a); NA, not available. Journal of Clinical Lipidology 2018 12, 390-396.e8DOI: (10.1016/j.jacl.2017.12.008) Copyright © 2018 National Lipid Association Terms and Conditions

Supplementary Figure 3 Percentage change from baseline in non-HDL-C at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 studytherefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; non-HDL-C, non-high-density lipoprotein cholesterol. Journal of Clinical Lipidology 2018 12, 390-396.e8DOI: (10.1016/j.jacl.2017.12.008) Copyright © 2018 National Lipid Association Terms and Conditions

Supplementary Figure 4 Percentage change from baseline in triglycerides at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; NA, not available. Journal of Clinical Lipidology 2018 12, 390-396.e8DOI: (10.1016/j.jacl.2017.12.008) Copyright © 2018 National Lipid Association Terms and Conditions